Endometrial Neoplasms
Conditions
Keywords
Oncology, Endometrial Cancer, Tislelizumab
Brief summary
The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.
Detailed description
This is a multicenter, prospective, single-arm open-label study designed to enhance surgical R0 resection rate, reduce residual lesions, decrease distant metastasis and disease recurrence rates, and prolong the survival of patients with advanced endometrial cancer (stage III-IVb FIGO 2023) by neoadjuvant chemotherapy combined with tislelizumab.
Interventions
DRUGTislelizumab
Tislelizumab 200mg D1 ,Q3W
DRUGPaclitaxel
Paclitaxel(175 mg/m2 ) D1,Q3W
DRUGCarboplatin
Carboplatin(AUC=5) D1,Q3W
Sponsors
Zhongnan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntary participation and signed informed consent form; 2. Age ≥18 years; 3. Eastern Cooperative Oncology Group performance status 0-1; 4. The International Federation of Gynecology and Obstetrics (FIGO 2023) stage III-IVb of endometrial cancer; 5. Has not received any systematic anti-tumor treatment for advanced diseases in the past; 6. Have measurable disease according to RECIST v1.1 criteria; 7. Patients must meet the following criteria for laboratory tests to ensure adequate organ function: * ANC ≥1,500/mm3, or ≥1.5×109/L * Platelet count≥75,000/mm3 or 75 x 109/L * Hemoglobin≥9 g/dL or ≥5.6 mmol/L * Glomerular filtration rate estimated（eGFR） according to the Chronic Kidney Disease Epidemiology Collaborative Group formula （CKD-EPI EQ6）was≥40 mL/ 1.73m2 * Serum total bilirubin ≤ 1.5x upper limit of normal range（ULN） * Both AST and ALT were ≤3 x ULN 8. The expected lifespan exceeds 3 months.
Exclusion criteria
1. Received PD-1 target therapy other than tislelizumab or other antibody or drug therapy that specifically targets T-cell costimulation or checkpoint channels within 6 months before enrollment； 2. Has human immunodeficiency virus infection, active viral hepatitis, and active tuberculosis infection； 3. Active leptomeningeal disease or uncontrolled, untreated brain metastases resulting in elevated intracranial pressure; 4. Major surgical procedures had been performed within 4 weeks before consent was obtained； 5. Other conditions deemed by the investigator to be ineligible for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection rate (R0 %) | Up to approximately 24 months | R0 resection rate is defined as the percentage of eligible patients that underwent a microscopically complete (or R0) resection. The resection is considered R0 if the inked margin is further than 1 mm distinct from any tumour cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR%) | Up to approximately 24 months | ORR (either confirmed complete response \[CR\] or partial response \[PR\]) based on RECIST 1.1 will be determined in participants who have measurable disease at study entry. |
| Progression free survival (PFS) | Up to approximately 24 months | PFS is defined as the time from the date of first dose to the earlier date of assessment of progression or death by any cause. |
| Pathological complete response rate (pCR%） | Up to approximately 24 months | pCR is defined as the absence of invasive cells at microscopic examination of the primary tumor and lymph nodes at surgery. Any remaining in-situ lesions are permissible. |
| Overall survival (OS) | Up to approximately 24 months | OS is defined as time from first dose of study intervention to death from any cause. |
| Incidence and severity of adverse events as assessed by the NCI-CTCAE v5.0 | Up to approximately 24 months | Safety and tolerability |
| Recurrence free survival (RFS) | Up to approximately 24 months | RFS is defined as the time from metastasectomy until progression by RECIST 1.1 or death from any cause. |
Countries
China
Contacts
Primary ContactZheng Hu, MD,PhD
Outcome results
None listed